EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Therapeutic failure reported with HIV long‐acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024

Kenneth L McCall iD, Danielle L Cabral, Jamie F Coghlan, Ashante M Concepcion, Kristine E Denimarck, Shawn S Shalumov

HIV Medicine · 2025

DOI: 10.1111/hiv.13709 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von Kenneth L McCall und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Binghamton University School of Pharmacy & Pharmaceutical Sciences, Johnson City, New York, USA. Hauptthemen laut MEDLINE: HIV Infections, Adverse Drug Reaction Reporting Systems, Anti-HIV Agents, Rilpivirine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We examined adverse event (AE) reports relating to cabotegravir/rilpivirine (CAB/RPV) in the US FDA Adverse Event Reporting System (FAERS), focusing on therapeutic failure (TF) and non‐therapeutic failure (NTF) outcomes.

Methods

FAERS is a database of AE and medication error reports from post‐marketing surveillance. The study was granted exempt approval by the Binghamton University Institutional Review Board. We queried reports for CAB/RPV in the FAERS system from 1 January 2021 to 31 March 2024. TFs were defined as involving any of the following terms: viral load increased, virological failure, pathogen resistance, blood HIV RNA increased, treatment failure, drug ineffective, viral mutation identified, viraemia, and therapy non‐responder. The top 20 most common AEs were also identified. Means, standard deviations, and percentages were used to characterize the sample.

Results

The study cohort consisted of 2605 reports. The reported sex of the study cohort was 50% male ( n = 1295), 19% female ( n = 505), and 31% unspecified ( n = 805), with a mean ± standard deviation (SD) age of 46.9 ± 12.4 years ( n = 378). The top three most reported AEs were TFs, product dose omissions, and injection site pain, with 377 (14.5%), 354 (13.6%), and 331 (12.7%) cases, respectively. The mean ± SD weight of people with a report of TF versus NTF was 101.8 ± 33.4 kg and 87.7 ± 26.7 kg, respectively ( p = 0.0175).

Conclusion

Our findings suggest that healthcare professionals should have a heightened awareness of potential challenges with CAB/RPV administration, including TFs and dose omissions in real‐world settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAdverse Drug Reaction Reporting SystemsAnti-HIV AgentsRilpivirinePyridonesHumansMaleFemaleUnited StatesMiddle AgedUnited States Food and Drug AdministrationAdultTreatment FailureViral Load

Stichwörter der Autor:innen

HIVadverse eventscabotegravir/rilpivirinelong‐acting injectabletreatment failure

Substanzen

Anti-HIV AgentsRilpivirinePyridones

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Binghamton University School of Pharmacy & Pharmaceutical Sciences, Johnson City, New York, USA.
  • Center for Young Adult, Adolescent, and Pediatric HIV, Northwell Health, Great Neck, New York, USA.
  • Doctor of Pharmacy Candidate, Binghamton University School of Pharmacy & Pharmaceutical Sciences, Johnson City, New York, USA.

ORCID-Profile: Kenneth L McCall

Zitieren

APA

McCall, K. L., Cabral, D. L., Coghlan, J. F., Concepcion, A. M., Denimarck, K. E., & Shalumov, S. S. (2025). Therapeutic failure reported with HIV long‐acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024. HIV Medicine. https://doi.org/10.1111/hiv.13709

Vancouver

McCall KL, Cabral DL, Coghlan JF, Concepcion AM, Denimarck KE, Shalumov SS. Therapeutic failure reported with HIV long‐acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024. HIV Medicine. 2025. doi:10.1111/hiv.13709

BibTeX
@article{McCall2025,
  author = {McCall, Kenneth L and Cabral, Danielle L and Coghlan, Jamie F and Concepcion, Ashante M and Denimarck, Kristine E and Shalumov, Shawn S},
  title = {Therapeutic failure reported with HIV long‐acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.13709}
}
Kostenlos starten →